EAI045
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406836

CAS#: 1942114-09-1

Description: EAI045 ia a potent and selective EGFR inhbitor. EAI045 targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays.


Price and Availability

Size
Price

10mg
USD 90
100mg
USD 450
1g
USD 2150
Size
Price

25mg
USD 150
200mg
USD 750
2g
USD 3750
Size
Price

50mg
USD 250
500mg
USD 1250
5g
Ask price

EAI045, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406836
Name: EAI045
CAS#: 1942114-09-1
Chemical Formula: C19H14FN3O3S
Exact Mass: 383.074
Molecular Weight: 383.3974
Elemental Analysis: C, 59.52; H, 3.68; F, 4.96; N, 10.96; O, 12.52; S, 8.36


Synonym: EAI045; EAI-045; EAI 045.

IUPAC/Chemical Name: 2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide

InChi Key: YTUFHOKUFOQRDF-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H14FN3O3S/c20-12-5-6-15(24)14(9-12)16(17(25)22-19-21-7-8-27-19)23-10-11-3-1-2-4-13(11)18(23)26/h1-9,16,24H,10H2,(H,21,22,25)

SMILES Code: O=C(NC1=NC=CS1)C(C2=CC(F)=CC=C2O)N3CC4=C(C=CC=C4)C3=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance
to third-generation inhibitors in T790M-positive non-small cell lung cancer. J
Hematol Oncol. 2016 Jul 22;9(1):59. doi: 10.1186/s13045-016-0290-1. Review.
PubMed PMID: 27448564; PubMed Central PMCID: PMC4957905.

2: Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T,
Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY,
Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck
MJ. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 2016 May 25;534(7605):129-32. doi:
10.1038/nature17960. PubMed PMID: 27251290; PubMed Central PMCID: PMC4929832.